Financials in USD. Standardized financial statements.
A compact view of how Takeda Pharmaceutical Company Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $4.78T | $4.58T | $4.26T | $4.03T | $3.57T | $3.20T | $3.29T | $2.10T | $1.77T | $1.73T |
| Revenue Growth? | +4.3% | +7.5% | +5.9% | +12.8% | +11.6% | -2.8% | +56.9% | +18.5% | +2.2% | 0.0% |
| Cost of Revenue? | $2.34T | $1.58T | $1.43T | $1.24T | $1.11T | $994.31B | $1.09T | $659.69B | $495.92B | $558.75B |
| Gross Profit? | $2.44T | $3.00T | $2.83T | $2.78T | $2.46T | $2.20T | $2.20T | $1.44T | $1.27T | $1.17T |
| Gross Margin? | +51.1% | +65.5% | +66.4% | +69.1% | +69.0% | +68.9% | +66.9% | +68.5% | +72.0% | +67.7% |
| Operating Expenses? | $1.87T | $2.66T | $2.62T | $2.29T | $2.00T | $1.69T | $2.10T | $1.28T | $1.03T | $1.02T |
| Operating Income? | $573.04B | $342.59B | $214.07B | $490.50B | $460.84B | $509.27B | $100.41B | $204.97B | $241.79B | $155.87B |
| EBITDA? | $1.34T | $1.21T | $1.14T | $1.28T | $1.18T | $983.72B | $671.90B | $464.22B | $359.96B | $296.88B |
| Income Before Tax | $275.88B | $175.08B | $52.79B | $375.09B | $302.57B | $366.24B | -$60.75B | $94.90B | $217.21B | $143.35B |
| Income Tax Expense | $72.27B | $66.94B | -$91.41B | $58.05B | $72.41B | -$9.94B | -$105.04B | -$14.12B | $30.50B | $27.83B |
| Net Income? | $203.33B | $107.93B | $144.07B | $317.02B | $230.06B | $376.00B | $44.24B | $109.13B | $186.89B | $114.94B |
| EPS? | $63.91 | $34.17 | $46.05 | $102.15 | $73.57 | $120.36 | $14.21 | $34.78 | $119.68 | $73.58 |
| Diluted EPS? | $63.91 | $33.62 | $45.58 | $100.97 | $72.94 | $119.48 | $14.13 | $34.78 | $118.78 | $73.13 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality